Deepinder Goyal’s health-tech startup Temple has acquired London-based Longevous, an evidence-based longevity medicine practice, as the company strengthens its clinical and scientific capabilities ahead of the launch of its first wearable device. Financial details of the acquisition have not been disclosed. Longevous founders Dr. Robert Mohr and Dr. Avi Roy, along with their team, will join Temple full-time as part of the transaction.
The acquisition gives Temple additional expertise at a crucial stage of its development. Mohr will become the startup’s chief medical officer, while Roy will serve as head of science. Temple is developing a wearable designed to monitor cerebral blood flow and oxygenation in real time, and the Longevous team had already been working with Temple’s scientists to test its technology, examine its proprietary “Entropy” metric and review early scientific work.
Temple Acquires Longevous Ahead Of Wearable Launch
The acquisition represents a strategic move to bring clinical and scientific expertise inside Temple as the company moves from product development toward commercialization.
Longevous, based in London, operates as an evidence-based longevity medicine practice. Rather than simply acquiring technology, Temple is bringing its founders and team into the company, creating a direct link between the startup’s wearable technology and a clinical longevity practice.
Temple-Longevous Deal At A Glance
| Deal Particular | Details |
|---|---|
| Acquirer | Temple |
| Founder | Deepinder Goyal |
| Target | Longevous |
| Target location | London, UK |
| Target business | Evidence-based longevity medicine |
| Acquisition value | Undisclosed |
| Founders joining Temple | Dr. Robert Mohr, Dr. Avi Roy |
| Mohr’s new role | Chief Medical Officer |
| Roy’s new role | Head of Science |
| Longevous operations | Continues under Temple |
| Strategic objective | Clinical and scientific capability |
The deal is therefore primarily about expertise and integration rather than disclosed financial synergies.
Robert Mohr And Avi Roy Join Temple Leadership
Dr. Robert Mohr will take on the role of chief medical officer at Temple. He is a board-certified physician with nearly two decades of clinical experience and previously worked in emergency medicine before moving into evidence-based longevity medicine, with experience spanning preventive and precision medicine.
Dr. Avi Roy will become Temple’s head of science. Roy is an Oxford-trained biomedical scientist who has worked across longevity science and business. He previously co-founded Founders Health and UDA and worked as a research fellow at the University of Oxford’s Centre for the Advancement of Sustainable Medical Innovation.
New Roles At Temple
| Executive | Background | New Temple Role |
|---|---|---|
| Dr. Robert Mohr | Physician, longevity medicine | Chief Medical Officer |
| Dr. Avi Roy | Biomedical scientist, Oxford-trained | Head of Science |
| Longevous team | Clinical and longevity expertise | Temple science and clinical operations |
Mohr is expected to bring clinical rigor to Temple’s experiments and health-related claims, while Roy will work alongside the existing science team on research and validation.
How A Dinner In London Led To The Acquisition
Goyal said the deal originated from an informal meeting with Mohr and Roy at a dinner in London several months ago.
The two noticed the Temple device Goyal was wearing and began asking questions about its technology and the science behind it. The conversation eventually led them to try the wearable themselves.
Mohr and Roy used Temple for about two months as their daily wearable and subsequently worked with the company’s science team to evaluate its data and assumptions.
Goyal said the pair challenged Temple’s assumptions and scrutinized its vision rather than simply accepting the company’s claims. They subsequently became involved in validation work and reviewed Temple’s first scientific manuscripts before submission.
Dinner Meeting
↓
Temple Wearable Trial
↓
Technology And Data Testing
↓
Scientific Validation Work
↓
Full-Time Collaboration
↓
Longevous Acquisition
The unusual route from product testing to acquisition illustrates the importance Temple is placing on independent scientific scrutiny as it prepares for launch.
What Temple Is Building
Temple is developing an experimental wearable designed to sit around the temple area of the head rather than on the wrist like a conventional smartwatch or fitness tracker.
The company says the device is designed to continuously monitor cerebral blood flow and oxygenation levels in real time. Its technology is intended to generate physiological data related to brain and cognitive health.
Temple’s approach is differentiated from mainstream fitness wearables because of both the location of the device and the physiological signals it aims to measure.
Temple’s Product Strategy
| Area | Temple’s Approach |
|---|---|
| Form factor | Small temple-worn wearable |
| Primary focus | Brain and physiological monitoring |
| Key measurements | Cerebral blood flow and oxygenation |
| Proprietary metric | “Entropy” |
| Target use cases | Health, performance and longevity |
| Development stage | Pre-commercial launch |
| Initial markets | India and international markets |
The company has been preparing for commercial production and recently partnered with manufacturing companies Zetwerk and Ethereal Machines. It plans to initially manufacture a few thousand units for domestic and international markets.
Temple Has Raised $54 Million So Far
The Longevous acquisition comes months after Temple raised $54 million in seed funding.
The February 2026 round valued Temple at $190 million and included Peak XV Partners, Steadview Capital, Dharana Capital, Info Edge Ventures and more than 80 individual investors. Goyal personally invested ₹104 crore, accounting for about 21% of the round, according to The Economic Times.
The company subsequently reached a reported valuation of $375 million through an employee stock option liquidity program, nearly double its valuation at the time of the seed round.
Temple’s Funding And Valuation Timeline
| Milestone | Amount / Valuation |
|---|---|
| Seed funding, February 2026 | $54 million |
| Valuation at seed round | $190 million |
| Goyal’s personal investment | ₹104 crore |
| Reported ESOP liquidity valuation | $375 million |
| Increase from seed valuation | ~97% |
| Longevous acquisition value | Undisclosed |
The reported increase in valuation reflects investor expectations around Temple’s technology and commercial potential, although it does not establish that the wearable will ultimately achieve those expectations.
Goyal Is Building A Larger Longevity Portfolio
Temple is part of Goyal’s broader interest in longevity and health technology following his transition away from the chief executive role at Eternal, the parent company of Zomato and Blinkit.
Goyal has also committed substantial personal capital to Continue, a longevity research venture from which Temple originated. He has described longevity and aerospace as areas where he intends to focus on higher-risk experimentation.
This makes the Longevous acquisition part of a broader strategy rather than an isolated startup acquisition.
Goyal’s Post-Eternal Focus
Eternal / Zomato
→ Transition From CEO Role
→ Longevity Research
→ Temple Wearable
→ Clinical & Scientific Expertise
→ Potential Consumer Health Platform
The acquisition strengthens the clinical side of this strategy at a time when Temple is moving closer to selling its first product.
Scientific Validation Is Becoming A Core Priority
For a health-tech company making claims about physiological measurements, scientific validation can be particularly important.
Temple’s acquisition of Longevous gives the company direct access to physicians and biomedical researchers who can challenge product assumptions, assess experimental design and scrutinize claims.
This may help Temple avoid one of the major risks facing emerging health-tech companies: making claims that go beyond what the underlying evidence supports.
The Longevous founders had already been involved in this process before joining the company. Their decision to move full-time into Temple formalizes that relationship.
Longevous Will Continue Serving Existing Clients
Despite the acquisition, Longevous will continue operating as part of Temple rather than being immediately absorbed into the wearable business.
Goyal said Mohr and Roy will continue personally looking after the practice’s existing clients.
This structure could give Temple an operating clinical practice alongside its technology and research operations.
| Before Acquisition | After Acquisition |
|---|---|
| Longevous independent practice | Longevous operates under Temple |
| Mohr and Roy founders | Temple CMO and Head of Science |
| Separate clinical operation | Linked to Temple’s science team |
| Temple in-house science | Expanded with Longevous expertise |
| Wearable development | Wearable + clinical validation |
That combination could become strategically useful if Temple eventually builds services around the data collected by its wearable.
Commercialization Will Be The Next Major Test
Temple’s biggest upcoming milestone is the commercial launch of its wearable.
Goyal recently said the device had been reduced to less than half the size of its earlier version and described it as the smallest wearable by volume. The company has indicated that limited-edition pre-orders would begin ahead of shipments expected before the end of 2026.
The acquisition therefore comes at an important point in the product cycle.
Temple now needs to move from scientific development to manufacturing, customer adoption and real-world validation.
Key Challenges For Temple
The company faces several challenges as it approaches launch.
First, it must demonstrate that the wearable can reliably collect the physiological signals it promises to measure. Second, it needs to establish that those measurements have meaningful applications for consumers rather than simply producing interesting data.
Third, Temple must persuade consumers to pay for a specialized device when established companies already offer fitness and health wearables.
Temple’s Commercialization Checklist
| Challenge | Why It Matters |
|---|---|
| Sensor accuracy | Determines credibility of measurements |
| Scientific validation | Supports health-related claims |
| Manufacturing scale | Enables commercial availability |
| Battery and comfort | Influences daily usage |
| Consumer pricing | Determines addressable market |
| Data interpretation | Converts measurements into useful insights |
| Regulatory considerations | Important for health-related claims |
| Customer adoption | Determines commercial viability |
The acquisition of Longevous directly addresses one of these challenges: scientific and clinical credibility.
The Bigger Picture
Temple’s acquisition of Longevous signals that Deepinder Goyal’s health-tech venture is moving beyond hardware development toward a more integrated combination of wearable technology, scientific research and clinical expertise. Bringing the founders of an evidence-based longevity practice into senior roles could help Temple build stronger validation processes as it prepares to make health-related claims about its technology.
The deal also highlights the growing intersection between consumer wearables and longevity science. Temple is attempting to differentiate itself through measurements that conventional wrist-based devices do not target in the same way. Whether that technological distinction translates into meaningful consumer value will become clearer once the device reaches the market.
Looking Ahead
Temple’s immediate priorities will likely include completing validation work, scaling manufacturing and preparing its wearable for commercial launch. The continued operation of Longevous under Temple could give the company a real-world clinical environment in which to develop and test ideas while maintaining a relationship with existing longevity clients.
The acquisition also raises the stakes for Temple’s scientific claims. With Mohr as chief medical officer and Roy leading science, the company will have stronger internal expertise to challenge assumptions and evaluate evidence before making claims to consumers. If Temple can combine credible science, reliable hardware and a compelling user experience, the Longevous acquisition could become an important part of its transition from an experimental project into a commercial health-tech business.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
